Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape

被引：2

作者：

Capone, Giacomo ^{[1
]}

Eriksson, Bjoern ^{[2
]}

Al, Monique ^{[3
]}

van Belkum, Stan ^{[3
]}

Broich, Karl ^{[4
]}

Lamas, Maria ^{[5
]}

Lunzer, Marianne ^{[6
]}

Nolan, Lorraine ^{[7
]}

Ester, Catriona ^{[1
]}

Burgos, Juan Garcia ^{[1
]}

Pioppo, Laura ^{[1
]}

Zanoletty, Ana ^{[1
]}

Arlett, Peter ^{[1
]}

机构：

[1] European Med Agcy, Amsterdam, Netherlands

[2] Lakemedelsverket, Uppsala, Sweden

[3] Cent Comm Res Involving Human Subjects, The Hague, Netherlands

[4] Bundesinst Arzneimittel & Med Prod, Bonn, Germany

[5] Agencia Espanola Medicamentos & Prod Sanitarios, Madrid, Spain

[6] AGES MEA, Vienna, Austria

[7] Hlth Prod Regulatory Author, Dublin, Ireland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2024年 / 23卷 / 11期

关键词：

D O I：

10.1038/d41573-024-00085-5

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support better, faster and optimized clinical trials.

引用

页码：797 / 798

页数：2

共 50 条

[31] Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU
Verbruggen, Alfons
Coenen, Heinz H.
Deverre, Jean-Robert
Guilloteau, Denis
Langstrom, Bengt
Salvadori, Piero A.
Halldin, Christer
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (11) : 2144 - 2151
[32] The EU Clinical Trials Directive Jeopardises Consumer and Occupational Safety
Schnuch, Axel
Uter, Wolfgang
White, Ian R.
CONTACT DERMATITIS, 2011, 65 (05) : 251 - 253
[33] Availability of results of clinical trials registered on EU Clinical Trials Register: cross sectional audit study
DeVito, Nicholas J.
Morley, Jessica
Smith, James Andrew
Drysdale, Henry
Goldacre, Ben
Heneghan, Carl
BMJ MEDICINE, 2024, 3 (01):
[34] Phase I studies in EU: due change in compliance and transparency under the EU clinical trials regulation
Christian Martin De Mey
European Journal of Clinical Pharmacology, 2022, 78 : 1047 - 1048
[35] Phase I studies in EU: due change in compliance and transparency under the EU clinical trials regulation
De Mey, Christian Martin
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (06) : 1047 - 1048
[36] Clinical trials in paediatric haematology-oncology: are future successes threatened by the EU directive on the conduct of clinical trials?
Mitchell, Chris
ARCHIVES OF DISEASE IN CHILDHOOD, 2007, 92 (11) : 1024 - 1027
[37] Clinical Trials according to the Clinical Trials Regulation Application Procedure for Sponsors and Reporting Obligations via the EU Portal
Schweim, Janna K.
PHARMAZEUTISCHE INDUSTRIE, 2022, 84 (12): : 1417 - 1421
[38] Principles of the EU Clinical Trials Regulation No 536/2014 What will change?
Mende, Aylin
Frech, Marion
Riedel, Claudia
BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2017, 60 (08) : 795 - 803
[39] Input analysis for two public consultations on the EU Clinical Trials Regulation
Holger Langhof
Jonas Lander
Daniel Strech
Health Research Policy and Systems, 14
[40] Medicinal studies in palliative care: impact of the EU clinical trials directive
Spathis, Anna
PALLIATIVE MEDICINE, 2007, 21 (01) : 60 - 61

← 1 2 3 4 5 →